Virtual BPS
Virtual BPS are short, educational webinars meant to bring the latest in peptide research and clinical development to the scientific community.
2026 Boulder Peptide Symposium
The only confrence focused solely on the pharmaceutical development of peptide therapeutics
UPCOMING EVENT
Our next webinar will be Tuesday, December 9th, starting at 12:00 p.m. (EST). Yingnan Zhang, Paula Flórez (both from Genentech) and Susana Vázquez Torres (National Centre for Cancer Research in Madrid) will each present on how they are using artificial intelligence (AI) to designs peptides for venom-derived therapeutics and cures for venom toxins.
December 9, 2025, 12:00 PM-1:30 PM EST
Smart Poisons, Smart Cures: How AI Redefines Peptide Design
All talks are vetted by our Scientific Advisory Board for relevance and represent the latest example of therapeutic peptide technologies or related translational research. The webinar typically consists of two talks followed by Q&A sessions with the audience.
VBPS events are usually held quarterly and no upcoming events have been announced at this time.
VBPS 2025
Anthony Silvestri
Head of Chemistry
Unnatural Products
Tales of macrocycle medchem: leveraging peptide discovery and optimization technologies
Andre Watson
Chairman and CEO
Ligandal
Attaining Precision, Cell-Specific Targeted Gene Delivery with Peptide Direct Conjugates (PDC)™
Paula Flórez
Postdoctoral Researcher
Genentech
Overcoming Library Instability: Computational Design of Phage Display Libraries for Knottin Peptides
Yingnan Zhang
Senior Principal Scientist
Genentech
Harnessing Venom for Drug Discovery: Developing a High-Performance Venom Library Platform with a Machine Learning–Enabled Rapid Hit-to-Lead Workflow
Susana Vázquez Torres
Postdoctoral Researcher
National Centre for Cancer Research (CNIO) in Madrid
De novo designed proteins neutralize lethal snake venom toxins
VBPS 2024
Mar Albà
Professor
Hospital del Mar Research Institute and ICREA
Microproteins contribute to evolutionary innovation and cancer
Sebastiaan van Heesch
Group Leader
Princess Máxima Center for Pediatric Oncology and Oncode Institute
What can Ribo-seq, proteomics, and immunopeptidomics tell us about the non-canonical proteome?
Brian Roberts
Director of Preclinical Immunology
EpiVax, Inc.
Promiscuous T cell binding epitopes in two osteoporosis medications lead to different immunogenicity profiles: A Tale of Two Peptides
Daniela Verthelyi
Chief of the Immunology Lab in the Office of Pharmaceutical Quality Research
CDER, FDA
Innate Immune Response Modulating Impurities Testing as a component of immunogenicity risk assessments
VBPS 2023
Yvonne Ware
Associate Director, Manufacturing Operations
BioNTech SE
An overview of cGMP individualized peptide manufacturing for BNT221, an autologous neoantigen specific T cell product candidate for adoptive cell therapy of advanced or metastatic melanoma
Cary Potochnik
NAPP™ Team Lead
Polypeptide Group
Personalized Peptide Manufacture, a CMO approach
Jessica Kramer
Assistant Professor, Department of Biomedical Engineering
The University of Utah
Supramolecular Protein Stabilization with Zwitterionic Polypeptide-Cucurbit[7]uril Conjugates
Jakob Fuhrmann
Senior Principal Scientist
Genentech
Rational design and optimization of cell-permeable peptidic degraders
Maria Soloveychik
CEO
SyntheX
Developing a high throughput platform for the empirical discovery of molecular glues
VBPS 2022
Tyler Brown
Principal Scientist
i2O Therapeutics
Ionic Liquid Technology: Enabling the Oral Delivery of Peptides
John Gleeson
Senior Scientist, Biopharmaceutics
Merck
Delivering Oral Peptide Drugs: A Pediatric Perspective
Peter McNamara
Senior Vice President, Head of Research
Tectonic Therapeutic
Discovery of Therapeutic Antibodies that Target Specific GPCRs Using a Novel Discovery Platform
Sally Wang Liang
Senior Vice President Business Development
PepLib
Novel HTS-Compatible Peptide Discovery Platform for the Direct Identification of Functionally Active GPCR Ligands from Cell-based Screens
Yu-Shan Lin
Associate Professor
Tufts University
Structure Prediction of Cyclic Peptides via Molecular Dynamics + Machine Learning
Chris Bahl
Chief Scientific Officer and Co-founder
AI Proteins
De novo designed miniproteins have big potential for therapeutic development
Li Li
Principal Scientist
Merck Research Laboratories
Improving Oral Bioavailability of Poorly-Permeable Peptides
Chengwei Wu
Senior Scientist
Merck Research Laboratories
From mRNA Lead to Drug Candidate-Discovery of a Novel, Potent, and Orally Bioavailable, Tricyclic Peptide PCSK9 Inhibitor
John Mumm
Founder and CEO
Deka Biosciences
Blending Natural Biology to Design Personal Therapeutics
Gaurav Bhardwaj
Assistant Professor of Medicinal Chemistry
The University of Washington and the Institute for Protein Design
Computational peptide design for diverse structures and functions
VBPS 2021
Weijun Shen
Director, Metabolic Diseases
CALIBR at Scripps Research
A Peptide Engineering Platform for PEG-FA Stapled Long-Acting Peptide Hormones
Christian Heinis
Associate Professor
EPFL
Prolonging the Half-Life of Peptides Using an Engineered Albumin-Binding Peptide
Hiroaki Suga
Professor
University of Tokyo
Display of Pseudo-Natural Peptides and Product
Yana Reshetnyak
Professor
University of Rhode Island
Membrane-Inserting Peptides
VBPS 2020
Nazli Azimi
CEO
Bioniz
Peptide Modality: An Emerging Class of Multi-functional Cytokine Inhibitors
WATCH PAST VIRTUAL BPS
Nazli Azimi
CEO
Bioniz
Peptide Modality: An Emerging Class of Multi-functional Cytokine Inhibitors